BioSpace News Archive

MSL Solutions. Designed to grow and enhance both organizations’ ability to deliver world-class MSL services to pharma’s Medical Affairs function, the new offering blends Envision’s and Two Labs’ capabilities.

XSOLIS, a healthcare technology firm focused on improving healthcare operations, today announced that it has secured a $75 million minority growth investment from Brighton Park Capital.

Clovis Oncology, Inc., announced that Professor Dr. Richard P. Baum and Dr. Harshad R. Kulkarni, in conjunction with 3B Pharmaceuticals, published a retrospective report of their independent experience with FAP-2286 in named-patient use in The Journal of Nuclear Medicine.

Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, announced the appointment of Manjunath Ramarao, Ph.D., as senior vice president in its research and development team.

Techmer PM LLC and Cupron Inc. have struck a deal to strengthen and expand their long-standing partnership related to Cupron’s patented, copper-based antimicrobial technology.

Antibe Therapeutics Inc., a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, filed its financial and operating results for the fiscal year ended March 31, 2021.

Asklepios BioPharmaceutical , Inc. announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track Designation for the LION-101 gene therapy program.

Bellicum Pharmaceuticals, Inc. today announced it has entered into a license agreement with the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) and Massachusetts General Hospital (Mass General) covering certain intellectual property and technology rights regarding the company’s CaspaCIDe safety switch.

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updates for its Phase 1 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion and Phase 1/2 clinical trial evaluating darovasertib combination therapies in metastatic uveal melanoma.